Photocure ASA · OSL:PHO

Photocure ASA — J.P. Morgan Healthcare Conference 2018

24 slides from Photocure ASA's conference presentation, Jan 8, 2018

  1. Slide 1: Photocure ASA Corporate Presentation January 2018

    PHOTOCURE ASA CORPORATE PRESENTATION JANUARY 2018

  2. Slide 2: Disclaimer

    DISCLAIMER The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Photocure ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These statements are based on various as

  3. Slide 3: Photocure – Corporate Snapshot

    PHOTOCURE – CORPORATE SNAPSHOT Background Blue Light Cystoscopy with Pipeline Hexvix®/Cysview® Hexvix®/Cysview® expansion plan in Commercial stage company focused on urology place (sNDA filed with FDA; priority review) Improved detection, recurrence and progression rates in bladder cancer Exploring

  4. Slide 4: Photocure – Investment Highlights

    PHOTOCURE – INVESTMENT HIGHLIGHTS Commercial-stage company focused Value building opportunities on Urology anticipated in next 12 – 24 months • Hexvix®/Cysview® for improved detection and • Large untapped potential for Hexvix/Cysview management of bladder cancer in existing and new market ─ Improved

  5. Slide 5: Hexvix/Cysview Update

    Hexvix/Cysview Update

  6. Slide 6: The Current State of Bladder Cancer

    THE CURRENT STATE OF BLADDER CANCER Bladder cancer is 5TH most • Most expensive cancer : $96 - $187k / patient1 • 76,960 new US cases in 2016, 16,390 deaths common cancer in the EU / • Accounts for $3.7 billion in direct medical in US in 20163 4th most common cancer costs/year² • Lifetime risk of de

  7. Slide 7: Bladder Cancer – The Patient Experience: Symptoms, Diagnosis, Surveillance & Follow-up

    BLADDER CANCER – THE PATIENT EXPERIENCE: SYMPTOMS, DIAGNOSIS, SURVEILLANCE & FOLLOW-UP Symptoms • Hematuria (blood in urine) Suspicion for Recurrence • Urinary frequency or urgency • Dysuria (pain, discomfort) Operating Room Outpatient Setting Diagnosis & Treatment ≥ T2 Cystectomy Outpatient Setting

  8. Slide 8: Improving Bladder Cancer Management

    IMPROVING BLADDER CANCER MANAGEMENT BLC with Hexvix (EU) / Cysview (US) for improved detection and management of bladder cancer View of Bladder with use of WLC • Hexvix/Cysview is a colorless contrast solution that is used with a blue-light enabled cystoscope • First approved drug-device procedure;

  9. Slide 9: Hexvix/Cysview A Global Specialty Brand

    HEXVIX/CYSVIEW A GLOBAL SPECIALTY BRAND In-Market Unit Sales Increased Sales and Blue Light Cystoscopes Sales revenues in 2016 increased YoY 11% to NOK 136M ($16.2M). YTD Q3 revenue increase YoY 10% to NOK 110M ($13.2M) Sales revenues comprise: • Own sales of Hexvix in the Nordic region • Own sales

  10. Slide 10: Cysview US Driving Accelerated Growth

    Cysview US Driving Accelerated Growth

  11. Slide 11: Cysview US Driving Accelerated Growth

    CYSVIEW US DRIVING ACCELERATED GROWTH Grow Body of Expand Product Build Market Clinical Evidence & Execute Sales Plan Pipeline & Market Awareness Recommendation Opportunity • Educate surgeons and • On-going, real world registry • Expand sales teams, • Introduction of the BLFC - develop advocates stu

  12. Slide 12: Building Awareness: Inclusion in National Guidelines

    BUILDING AWARENESS: INCLUSION IN NATIONAL GUIDELINES Transforming Clinical Practice • US Guidelines: Use of Blue Light Cystoscopy with Hexvix/Cysview receives highest level of recommendation in the new AUA/SUO bladder cancer guideline ─ Recommended based on the large body of evidence supporting both

  13. Slide 13: Grow Body of Clinical Evidence: Increasing Exposure in Medical Community

    GROW BODY OF CLINICAL EVIDENCE: INCREASING EXPOSURE IN MEDICAL COMMUNITY Increased Exposure to Urologists Continued Positive Data Flow Fuels Forward Momentum • New publications in Bladder Cancer show Blue Light Cystoscopy (BLC) with Hexvix/Cysview significantly improves long term outcomes • Signific

  14. Slide 14: Execute Sales Plan: Maximizing Sales Efficiency Targeting Top 25 Markets

    EXECUTE SALES PLAN: MAXIMIZING SALES EFFICIENCY TARGETING TOP 25 MARKETS Top 25 markets – TURBT rank Example anchor accounts Comments Totals (inpatient & Metropolitan statistical area outpatient TURBT procedures*): Total New York, Newark, Jersey 21,284 • Focus efforts to establish and build Chicago,

  15. Slide 15: Expansion into Larger Segments: Market Opportunity in the Surveillance Segment

    EXPANSION INTO LARGER SEGMENTS: MARKET OPPORTUNITY IN THE SURVEILLANCE SEGMENT • Expansion with Blue Light Flexible Cystoscopy with Cysview • For office settings (surveillance and first diagnostic) that utilize flexible cystoscopes Segments of the Global Cystoscopy Market CURRENT TURBT PROCEDURES TU

  16. Slide 16: Expansion into Larger Segments: Phase 3 Clinical Trial Results Reported at AUA 2017

    EXPANSION INTO LARGER SEGMENTS: PHASE 3 CLINICAL TRIAL RESULTS REPORTED AT AUA 2017 Overview Endpoints Conclusion • Compare use of Blue Light • Primary endpoint - the rate at • BLFCC significantly improves the Cystoscopy with Cysview and which malignancy is detected with detection of patients with r

  17. Slide 17: Expansion into Larger Segments: Supplemental New Drug Application – Priority Review

    EXPANSION INTO LARGER SEGMENTS: SUPPLEMENTAL NEW DRUG APPLICATION – PRIORITY REVIEW • Expanded indications to include combination of Cysview with KARL STORZ Flexible Videoscope System in addition to current Rigid Scope System targeting surveillance cystoscopies of patients diagnosed NMIBC – Of the t

  18. Slide 18: US Medicare Reimbursement of an Additional USD 1,000 per TURBT from 2018

    US MEDICARE REIMBURSEMENT OF AN ADDITIONAL USD 1,000 PER TURBT FROM 2018* Medicare (~55% of TURBT) Private payer (~45% of TURBT) • Procedure fee for cystoscopy • Procedure fee for cystoscopy • Cysview paid at contracted rate (ASP** +6 to Cystoscopy • Cysview paid at ASP** +6% 15%) • No change from 2

  19. Slide 19: Cysview US Continued Strong Momentum

    CYSVIEW US CONTINUED STRONG MOMENTUM • Photocure own sales revenue in the US in 3Q Approval in increased 45% YoY surveillance market – Driven by YoY in-market volume growth of 39% in third quarter Receive reimbursement code in – 6th quarter with QoQ sales revenue growth in Increase US US market the

  20. Slide 20: Non-Urology Pipeline

    Non-Urology Pipeline

  21. Slide 21: Cevira & Visonac Phase 3 Ready Products with Significant Sales Potential

    CEVIRA & VISONAC PHASE 3 READY PRODUCTS WITH SIGNIFICANT SALES POTENTIAL • Cevira - Breakthrough single use and fully integrated drug-device technology to satisfy high need for novel non-surgical therapies to treat global epidemic of HPV/HSIL populations • Visonac – Novel topical non-antibiotic/non-

  22. Slide 22: Financials

    Financials

  23. Slide 23: Key Financials – YTD Q3 2017

    KEY FINANCIALS – YTD Q3 2017 Income Statement - Segments • YTD Q3 Hexvix/Cysview revenues driven by US ─ US sales +46%. Installed base of BLC at 96 (YE 2016: MUSD YTD '17 YTD '16 Change 83) Commercial Franchise ─ Nordic revenues improved from a slow start of the Nordic revenues 3.7 3.5 4% year. 4% i

  24. Slide 24: Photocure – Investment Highlights

    PHOTOCURE – INVESTMENT HIGHLIGHTS Commercial-stage company focused Value building opportunities on Urology anticipated in next 12 – 24 months • Hexvix®/Cysview® for improved detection and • Large untapped potential for Hexvix/Cysview management of bladder cancer in existing and new market ─ Improved

Photocure — J.P. Morgan Healthcare Conference 2018 on 6ix